Hepatocellular Carcinoma

CHF 143.95
Auf Lager
SKU
K6BMH7V587P
Stock 1 Verfügbar
Geliefert zwischen Do., 13.11.2025 und Fr., 14.11.2025

Details

This book provides a comprehensive overview of the current limitations and unmet needs in Hepatocellular Carcinoma (HCC) diagnosis, treatment, and prevention. It also provides newly emerging concepts, approaches, and technologies to address challenges. Topics covered include changing landscape of HCC etiologies in association with health disparities, framework of clinical management algorithm, new and experimental modalities of HCC diagnosis and prognostication, multidisciplinary treatment options including rapidly evolving molecular targeted therapies and immune therapies, multi-omics molecular characterization, and clinically relevant experimental models. The book is intended to assist collaboration between the diverse disciplines and facilitate forward and reverse translation between basic and clinical research by providing a comprehensive overview of relevant areas, covering epidemiological trend and population-level patient management strategies, new diagnostic and prognostic tools, recent advances in the standard care and novel therapeutic approaches, and new concepts in pathogenesis and experimental approaches and tools, by experts and opinion leaders in their respective fields.

By thoroughly and concisely covering whole aspects of HCC care, Hepatocellular Carcinoma serves as a valuable reference for multidisciplinary readers, and promotes the development of personalized precision care strategies that lead to substantial improvement of disease burden and patient prognosis in HCC.


Provides a new strategy to advance the clinical care of patients. Provides a comprehensive overview of HCC diagnosis, treatment, and prevention. Written by experts in the field.

Autorentext

Yujin Hoshida
University of Texas Southwestern Medical Center
Dallas, TX
USA


Inhalt

Part 1: Clinical demographics and management.- 1. Risk Factors of Hepatocellular Carcinoma for Precision Personalized Care.- 2. Hepatocellular Carcinoma Surveillance and Staging.- 3. Changing Epidemiology of Hepatocellular Carcinoma and Role of Surveillance.- Part 2: Diagnosis and prognostication.- 4. Radiological diagnosis and characterization of HCC.- 5. Analysis of Hepatocellular Carcinoma Tissue for Biomarker and Therapeutic Target Discovery.- 6. Molecular subtypes and genomic signatures of hepatocellular carcinoma for prognostication and therapeutic decision making.- 7. Liquid Biopsy in Hepatocellular Carcinoma.- Part 3: Treatment.- 8. Surgical Therapies in Hepatocellular Carcinoma.- 9. Interventional Radiologic Therapies for Hepatocellular Carcinoma: From Where We Began To Where We Are Going.- 10. Precision Locoregional Therapies for Hepatocellular Carcinoma: Percutaneous Ablation and Radiotherapy.- 11. Molecular-targeted therapies in hepatocellular carcinoma.- 12. Immune therapies.- 13. Prevention Strategies for Hepatocellular Carcinoma.- Part 4: Molecular pathogenesis and therapeutic discovery.- 14. Molecular Alterations and Heterogeneity in Hepatocellular Carcinoma.- 15. Stromal and Immune Drivers of Hepatocarcinogenesis.- 16. Experimental Models for Preclinical Research in Hepatocellular Carcinoma. <p

Weitere Informationen

  • Allgemeine Informationen
    • Sprache Englisch
    • Editor Yujin Hoshida
    • Titel Hepatocellular Carcinoma
    • Veröffentlichung 20.08.2019
    • ISBN 3030215393
    • Format Fester Einband
    • EAN 9783030215392
    • Jahr 2019
    • Größe H241mm x B160mm x T25mm
    • Untertitel Translational Precision Medicine Approaches
    • Gewicht 810g
    • Auflage 1st edition 2019
    • Genre Medizin
    • Lesemotiv Verstehen
    • Anzahl Seiten 384
    • Herausgeber Springer International Publishing
    • GTIN 09783030215392

Bewertungen

Schreiben Sie eine Bewertung
Nur registrierte Benutzer können Bewertungen schreiben. Bitte loggen Sie sich ein oder erstellen Sie ein Konto.
Made with ♥ in Switzerland | ©2025 Avento by Gametime AG
Gametime AG | Hohlstrasse 216 | 8004 Zürich | Schweiz | UID: CHE-112.967.470